鲁索替尼乳膏(Opzelura)导致的不良反应怎么治疗？

Introduction: Ruxolitinib Cream (Opzelura) is indicated for the topical short-term and non-sustaining chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and pediatric patients 12 years and older whose condition cannot be adequately controlled by topical prescription therapies or is not suitable for topical prescription therapies.

Adverse reactions caused by ruxolitinib cream (Opzelura)

1. In atopic dermatitis, the most common adverse reactions include nasopharyngitis, diarrhea, bronchitis, ear infection, increased eosinophil count, urticaria, folliculitis, tonsillitis, runny nose, etc.

2. In non-segmental vitiligo, the most common adverse reactions are acne at the application site, itching at the application site, nasopharyngitis, headache, urinary tract infection, erythema at the application site, and fever.

Also includes bronchitis, ear infections, increased eosinophil count, hives, folliculitis, tonsillitis and rhinorrhea. Patients should have regular physical exams, including blood tests and skin exams, to monitor for potential side effects.

How to treat adverse reactions caused by ruxolitinib cream (Opzelura)

1. Skin irritation and itching: Skin irritation, itching or burning may occur in the early stages of use. These side effects are usually temporary and may gradually lessen after a few days of continued use. If symptoms persist or worsen, you should consult your doctor.

2. Acne: Keep your skin clean and hygienic, and avoid using irritating care products. If your acne is severe, your medication may need to be adjusted or other treatments may need to be taken.

3. Risk of infection: If signs of infection occur during use, such as redness, swelling, exudation, local temperature increase, etc., you should contact your doctor immediately for anti-infection treatment.

Patients should understand the potential risks and precautions of the drug. For example, ruxolitinib cream may increase the risk of thrombosis, including serious complications such as deep vein thrombosis and pulmonary embolism. Before using drugs, you should fully understand the potential risks and conduct necessary examinations and monitoring under the guidance of a doctor.

Precautions for ruxolitinib cream (Opzelura)

1. Serious infection: Patients who use JAK inhibitors to treat inflammation are at risk of serious infection, which may lead to hospitalization or death.

2. Malignant tumors: Lymphoma and other malignant tumors have been observed in patients treated with JAK inhibitors for inflammation.

Ruxolitinib cream should be stored at a temperature of 20°C-25°C, with an allowed excursion range of 15°C-30°C. Patients should strictly follow the doctor's instructions and contact the doctor immediately if any adverse reactions occur.